Abstract
Tuberculosis (TB) is a major health threat worldwide. TB is concentrated in prisons, where TB preventive therapy (TPT) implementation has been limited. Prisons generally, and especially in Malaysia, are overcrowded, minimally resourced, and have high prevalence of latent TB.
As prison personnel are largely responsible for TPT implementation, their perspectives were sought to identify barriers and potential solutions for implementing TPT in Malaysia’s largest prison. A focus group using nominal group technique (NGT) was conducted with 9 prison officers with experience related to TPT to generate a list and rank-order the top TPT barriers. The process was repeated to assess facilitators.
The top three barriers to implementing TPT were: 1) disruptions involved in prison activities (e.g., intra- and extra-prison transfers; 8 votes); 2) insufficient workforce (5 votes), and unanticipated inter-prison transfers (4 votes). Potential solutions included implementing care coordination protocols between officers and medical staff (8 votes), placing a medical hold until TPT completion (5 votes), and improving medication delivery logistics (4 votes). All prison officers supported a short-course TPT regimen administered once-weekly for 12 weeks (i.e. rifapentine and isoniazid (3HP)), over a daily TPT regimen for 6 months (i.e. isoniazid (26H)), due to less logistics and staff time required.
From the perspective of prison officer stakeholders, logistical constraints commonly observed in prisons were perceived to impact the implementation of TPT, yet they prioritized pragmatic solutions that align with known implementation strategies to employ to optimize TPT delivery, including developing stakeholder relationships between medical and prison personnel and changing infrastructure to address frequent transfers within and between prisons and the community.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
NIH Grant #R01DA041271
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by the Institutional Review Boards at Yale University (#2000020053) and the Universiti Malaya (#17-19-33974), and the Medical Research & Ethics Committee (MREC) at the Malaysian Ministry of Health (#NMRR ID-17-19-33974), with approval from the Malaysian Prison’s Department.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Disclosures: SS’s spouse worked for Merck pharmaceuticals 1997-2007 and retains company stock in his retirement account. There is no conflict of interest, but it is included in the interest of full disclosure.
Data Availability
The data are included in the manuscript.
